Dublin-based startup Aerska launched with a $21 million seed funding round to develop technology that transports RNA interference (RNAi) therapeutics across the blood-brain barrier. This addresses a critical delivery challenge in treating neurological diseases with RNA-based medicines. By enabling efficient brain targeting, Aerska aims to expand RNA drug applications beyond systemic indications and potentially treat conditions such as neurodegenerative and psychiatric disorders. The company operates between Ireland and the U.K., focusing on precision RNA delivery.